Suchen
Adaptimmune Therapeutics PLC
ADAPZur Watchlist hinzufügen
0.055USD
0.0000.00%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
10.34MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Adaptimmune Therapeutics PLC Unternehmen
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Adaptimmune Therapeutics PLC Informationen
BörsenkürzelADAP
Name des UnternehmensAdaptimmune Therapeutics PLC
IPO-datumMay 06, 2015
CEORawcliffe (Adrian George)
Anzahl der mitarbeiter506
WertpapierartDepository Receipt
GeschäftsjahresendeMay 06
Addresse60 Jubilee Avenue
StadtABINGDON
BörseNASDAQ Capital Market Consolidated
LandUnited Kingdom
PostleitzahlOX14 4RX
Telefon441235430000
Websitehttps://www.adaptimmune.com/
BörsenkürzelADAP
IPO-datumMay 06, 2015
CEORawcliffe (Adrian George)
Führungskräfte von Adaptimmune Therapeutics PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Priti Hegde, Ph.D.
Dr. Priti Hegde, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Adaptimmune Therapeutics PLC?
Die fünf größten Anteilseigner von Adaptimmune Therapeutics PLC sind: Dr. Garry E. Menzel, Ph.D.
Wie viele Institutionen halten Anteile an Adaptimmune Therapeutics PLC (ADAP)?
Mit Stand vom 2026Q1 halten 159 Institutionen Anteile an Adaptimmune Therapeutics PLC, mit einem Gesamtmarktwert von etwa 1.79M, was 0.67% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -156325066.00 gestiegen.